Therapeutic targeting of BET bromodomain and other epigenetic acetylrecognition domain–containing factors
Current Opinion in Genetics & Development · 2024-06 · 86 · 102181
DOI: 10.1016/j.gde.2024.102181 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Current Opinion in Genetics & Development, 2024-06. Verfasst von Sarah Gold und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry and Molecular Genetics, Simpson Querrey Institute for Epigenetics, Northwestern University Feinberg School of Medicine, Ch…. Hauptthemen laut MEDLINE: Transcription Factors, Epigenesis, Genetic, Neoplasms, Cell Cycle Proteins. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 83 Literaturangaben.
Abstract (Originalsprache)
Development of cancer therapies targeting chromatin modifiers and transcriptional regulatory factors is rapidly expanding to include new targets and novel targeting strategies. At the same time, basic molecular research continues to refine our understanding of the epigenetic mechanisms regulating transcription, gene expression, and oncogenesis. This mini-review focuses on cancer therapies targeting the chromatin-associated factors that recognize histone lysine acetylation. Recently reported safety and efficacy are discussed for inhibitors targeting the bromodomains of bromodomain and extraterminal domain (BET) family proteins. In light of recent results indicating that the transcriptional regulator BRD4-PTEFb can function independently of BRD4's bromodomains, the clinical trial performance of these BET inhibitors is placed in a broader context of existing and potential strategies for targeting BRD4-PTEFb. Recently developed therapies targeting bromodomain-containing factors within the SWI/SNF (BAF) family of chromatin remodeling complexes are discussed, as is the potential for targeting the bromodomain-containing transcription factor TAF1 and the YEATS acetylrecognition domain-containing factor GAS41. Recent findings regarding the selectivity and combinatorial specificity of acetylrecognition are highlighted. In conclusion, the potential for further development is discussed with a focus on proximity-based therapies targeting this class of epigenetic factors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Biochemistry and Molecular Genetics, Simpson Querrey Institute for Epigenetics, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA. Electronic address: https://twitter.com/@rwx_lif…
- Department of Biochemistry and Molecular Genetics, Simpson Querrey Institute for Epigenetics, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA. Electronic address: ASH@northwestern.edu.
Zitieren
APA
Gold, S., & Shilatifard, A. (2024). Therapeutic targeting of BET bromodomain and other epigenetic acetylrecognition domain–containing factors. Current Opinion in Genetics & Development, 86, 102181. https://doi.org/10.1016/j.gde.2024.102181
Vancouver
Gold S, Shilatifard A. Therapeutic targeting of BET bromodomain and other epigenetic acetylrecognition domain–containing factors. Current Opinion in Genetics & Development. 2024;86:102181. doi:10.1016/j.gde.2024.102181
BibTeX
@article{Gold2024,
author = {Gold, Sarah and Shilatifard, Ali},
title = {Therapeutic targeting of BET bromodomain and other epigenetic acetylrecognition domain–containing factors},
journal = {Current Opinion in Genetics & Development},
year = {2024},
volume = {86},
pages = {102181},
doi = {10.1016/j.gde.2024.102181}
}
EUVIMED